tradingkey.logo
tradingkey.logo
Search

Liminatus Pharma Surges Over 5% After Announcing $500M BNB Investment Strategy

TradingKey
AuthorBlock Tao
Jul 28, 2025 12:29 PM
facebooktwitterlinkedin
View all comments0

TradingKey – On Monday, July 28, Nasdaq-listed Liminatus Pharma Inc. (LIMN) jumped 5.28% in pre-market trading after unveiling plans to launch a dedicated crypto subsidiary focused on Binance Coin (BNB).

Liminatus Pharma Stock Chart – Source: Google

Liminatus Pharma Stock Chart – Source: Google

Liminatus, a preclinical-stage cancer immunotherapy company, announced it will form a new subsidiary called “American BNB Strategy” to manage and invest in BNB, the native token of the Binance ecosystem.

  • The company aims to raise up to $500 million, deploying funds in phased investments targeting long-term BNB accumulation
  • This move positions Liminatus alongside other corporate BNB holders like Nano Labs (NA), which currently holds 128,000 BNB

Coincidentally, the price of BNB soared above $850 today, setting a new record high. In the past 24 hours, BNB rose by more than 6%, reaching a high of $859 and temporarily reported at $849.

altText

BNB price chart (1 hour), source: TradingView

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

tradingkey.logo
* References, analysis, and trading strategies are provided by the third-party provider, Trading Central, and the point of view is based on the independent assessment and judgement of the analyst, without considering the investment objectives and financial situation of the investors.
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.